Cargando…
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
BACKGROUND: One of the significant tumor immune escape mechanisms and substantial barrier for successful immunotherapy is tumor-mediated inhibition of immune response through cell-to-cell or receptor/ligand interactions. Programmed death receptor-1 (PD-1) interaction with its ligands, PD-L1 and PD-L...
Autores principales: | Mkrtichyan, Mikayel, Chong, Namju, Abu Eid, Rasha, Wallecha, Anu, Singh, Reshma, Rothman, John, Khleif, Samir N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019896/ https://www.ncbi.nlm.nih.gov/pubmed/24829751 http://dx.doi.org/10.1186/2051-1426-1-15 |
Ejemplares similares
-
Lm-LLO-Based Immunotherapies and HPV-Associated Disease
por: Wallecha, Anu, et al.
Publicado: (2012) -
Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment
por: Wallecha, Anu, et al.
Publicado: (2013) -
Lm-LLO immunotherapies targeting multiple antigens and their impact on different mechanisms in the tumor microenvironment
por: Wallecha, Anu, et al.
Publicado: (2014) -
High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer
por: Ghamande, Sharad, et al.
Publicado: (2015) -
A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial
por: Gnanandarajah, Josephine S, et al.
Publicado: (2014)